Biogen Inc. share price today

(BIIB)

Biogen Inc. share price is $164.23 & ₹13,907.82

$164.23

▲

3.6

(2.24%)

Market is closed - opens 8 PM, 03 Dec 2024

View live Biogen Inc. share price in Dollar and Rupees. Guide to invest in Biogen Inc. from India. Also see the sentimental analysis on Indian investors investing in Biogen Inc.. Get details on the Indian mutual funds that are investing in Biogen Inc.. Get Analyst recommendations and forecasts along with all the Biogen Inc.'s financials.

Biogen Inc. share price movements

$160.25
$165.25
$164.23
2.43%
Downside
Day's Volatility :3.03%
Upside
0.62%
$153.62
$268.30
$164.23
6.46%
Downside
52 Weeks Volatility :42.74%
Upside
38.79%

Biogen Inc. Returns

Period	Biogen Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-19.83%	-6.2%	13.2%
6 Months	-29.86%	1.7%	15.3%
1 Year	-29.47%	11.6%	35.6%
3 Years	-26.72%	12.9%	28.6%

Biogen Inc. Key Statistics

in dollars & INR

Market Capitalization	$23.4B
Revenue TTM	$9.6B
EBITDA	$2.9B
Earnings Per Share (EPS)	$11.07
PE Ratio	14.51
Profit Margin	16.81%
Quarterly Earnings Growth YOY	-0.02%
Return On Equity TTM	10.47%

How to invest in Biogen Inc. from India?

It is very easy for Indian residents to invest directly in Biogen Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biogen Inc. stock in both rupees (INR) and dollars (USD). Search for Biogen Inc. or BIIB on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biogen Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biogen Inc. shares which would translate to 0.005 fractional shares of Biogen Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Biogen Inc.

33.82%

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Investment in Biogen Inc. from India has grown in the last 30 days as on Dec 3, 2024. 33.82% more purchase transactions for Biogen Inc. in the last 30 days versus the previous period.

-11%

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Search volume for Biogen Inc. on INDmoney from India has reduced in the last 30 days as on Dec 3, 2024. -11% less investors are searching Biogen Inc. in the last 30 days versus the previous period.

Indian Mutual Funds that own Biogen Inc.

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	1252	-6.91	0.05%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	26352	-4976.05	1.20%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	1887	-33.36	0.17%

Global Institutional Holdings in Biogen Inc.

Vanguard Group Inc
11.45%
PRIMECAP Management Company
11.20%
BlackRock Inc
9.98%
State Street Corp
5.04%
Wellington Management Company LLP
3.52%
JPMorgan Chase & Co
3.50%

Analyst Recommendation on Biogen Inc.

Buy

71%Buy

28%Hold

0%Sell

Based on 42 Wall street analysts offering stock ratings for Biogen Inc.(by analysts ranked 0 to 5 stars)

Based on 42 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biogen Inc.

What analysts predicted

Upside of 54.82%

Current:

$164.23

Target:

$254.26

Insights on Biogen Inc.

Increasing Revenue
Revenue is up for the last 3 quarters, 2.20B → 2.46B (in $), with an average increase of 5.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 583.6M → 388.5M (in $), with an average decrease of 33.4% per quarter
Vs LLY
In the last 1 year, Eli Lilly And Company has given 36.9% return, outperforming this stock by 66.9%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 225.7% return, outperforming this stock by 252.4%

Biogen Inc. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$13.5B	↑ 9.61%
Net Income	$4.4B	↑ 74.5%
Net Profit Margin	32.93%	↑ 12.24%

	FY19	Y/Y Change
Revenue	$14.4B	↑ 6.88%
Net Income	$5.9B	↑ 32.9%
Net Profit Margin	40.96%	↑ 8.03%

	FY20	Y/Y Change
Revenue	$13.4B	↓ 6.49%
Net Income	$4.0B	↓ 32.06%
Net Profit Margin	29.76%	↓ 11.2%

	FY21	Y/Y Change
Revenue	$11.0B	↓ 18.32%
Net Income	$1.6B	↓ 61.1%
Net Profit Margin	14.17%	↓ 15.59%

	FY22	Y/Y Change
Revenue	$10.2B	↓ 7.36%
Net Income	$3.0B	↑ 95.8%
Net Profit Margin	29.95%	↑ 15.78%

	FY23	Y/Y Change
Revenue	$9.8B	↓ 3.32%
Net Income	$1.2B	↓ 61.89%
Net Profit Margin	11.81%	↓ 18.14%

	Q2 FY23	Q/Q Change
Revenue	$2.5B	↓ 0.28%
Net Income	$591.6M	↑ 52.51%
Net Profit Margin	24.09%	↑ 8.34%

	Q3 FY23	Q/Q Change
Revenue	$2.5B	↑ 3.03%
Net Income	$-68.1M	↓ 111.51%
Net Profit Margin	-2.69%	↓ 26.78%

	Q4 FY23	Q/Q Change
Revenue	$2.4B	↓ 5.69%
Net Income	$249.7M	↓ 466.67%
Net Profit Margin	10.46%	↑ 13.15%

	Q1 FY24	Q/Q Change
Revenue	$2.2B	↓ 7.79%
Net Income	$393.4M	↑ 57.55%
Net Profit Margin	17.88%	↑ 7.42%

	Q2 FY24	Q/Q Change
Revenue	$2.4B	↑ 6.94%
Net Income	$583.6M	↑ 48.35%
Net Profit Margin	24.8%	↑ 6.92%

	Q3 FY24	Q/Q Change
Revenue	$2.5B	↑ 4.79%
Net Income	$388.5M	↓ 33.43%
Net Profit Margin	15.76%	↓ 9.04%

	FY18	Y/Y Change
Total Assets	$25.3B	↑ 6.92%
Total Liabilities	$12.3B	↑ 10.88%

	FY19	Y/Y Change
Total Assets	$27.2B	↑ 7.69%
Total Liabilities	$13.9B	↑ 13.36%

	FY20	Y/Y Change
Total Assets	$24.6B	↓ 9.6%
Total Liabilities	$13.9B	↑ 0.27%

	FY21	Y/Y Change
Total Assets	$23.9B	↓ 3.01%
Total Liabilities	$12.9B	↓ 7.29%

	FY22	Y/Y Change
Total Assets	$24.6B	↑ 2.83%
Total Liabilities	$11.2B	↓ 13.56%

	FY23	Y/Y Change
Total Assets	$26.8B	↑ 9.33%
Total Liabilities	$12.0B	↑ 7.88%

	Q2 FY23	Q/Q Change
Total Assets	$25.2B	↑ 2.27%
Total Liabilities	$10.7B	↓ 1.06%

	Q3 FY23	Q/Q Change
Total Assets	$28.2B	↑ 12.07%
Total Liabilities	$13.7B	↑ 28.21%

	Q4 FY23	Q/Q Change
Total Assets	$26.8B	↓ 4.78%
Total Liabilities	$12.0B	↓ 12.16%

	Q1 FY24	Q/Q Change
Total Assets	$26.6B	↓ 1.03%
Total Liabilities	$11.4B	↓ 5.73%

	Q2 FY24	Q/Q Change
Total Assets	$26.8B	↑ 0.89%
Total Liabilities	$10.9B	↓ 3.87%

	Q3 FY24	Q/Q Change
Total Assets	$28.3B	↑ 5.63%
Total Liabilities	$12.0B	↑ 9.52%

	FY18	Y/Y Change
Operating Cash Flow	$6.2B	↑ 35.96%
Investing Cash Flow	$-2.0B	↓ 30.94%
Financing Cash Flow	$-4.5B	↑ 87.9%

	FY19	Y/Y Change
Operating Cash Flow	$7.1B	↑ 14.4%
Investing Cash Flow	$470.5M	↓ 122.99%
Financing Cash Flow	$-5.9B	↑ 31.05%

	FY20	Y/Y Change
Operating Cash Flow	$4.2B	↓ 40.25%
Investing Cash Flow	$-608.6M	↓ 229.35%
Financing Cash Flow	$-5.3B	↓ 10.03%

	FY21	Y/Y Change
Operating Cash Flow	$3.6B	↓ 13.95%
Investing Cash Flow	$-563.7M	↓ 7.38%
Financing Cash Flow	$-2.1B	↓ 60.43%

	FY22	Y/Y Change
Operating Cash Flow	$1.4B	↓ 61.97%
Investing Cash Flow	$1.6B	↓ 379.69%
Financing Cash Flow	$-1.8B	↓ 15.65%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$487.0M	↑ 6.96%
Investing Cash Flow	$-753.5M	↓ 20.93%
Financing Cash Flow	$-9.8M	↓ 77.42%

Biogen Inc. Technicals Summary

Sell

Neutral

Buy

Biogen Inc. is currently in a neutral trading position according to technical analysis indicators.

Biogen Inc. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biogen Inc.	-5.35%	-29.86%	-29.47%	-26.72%	-45.15%
Eli Lilly And Company	-0.79%	-3.94%	36.56%	224.69%	567.78%
Johnson & Johnson	-2.17%	4.74%	-2.57%	-5.0%	10.92%
Merck & Co. Inc.	-1.24%	-21.83%	-4.24%	37.03%	13.36%
Novo Nordisk A/s	-0.96%	-22.33%	7.68%	101.71%	280.83%
Abbvie Inc	-9.33%	12.11%	26.1%	49.79%	109.61%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biogen Inc.	14.51	14.51	6.24	16.42	0.1	0.05	NA	112.28
Eli Lilly And Company	85.43	85.43	0.75	13.16	0.65	0.14	0.01	15.83
Johnson & Johnson	25.65	25.65	0.92	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	21.26	21.26	0.07	7.75	0.28	0.11	0.03	17.58
Novo Nordisk A/s	34.03	34.03	1.59	22.7	0.89	0.21	0.01	27.07
Abbvie Inc	63.74	63.74	0.44	10.93	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biogen Inc.	Buy	$23.4B	-45.15%	14.51	16.81%
Eli Lilly And Company	Buy	$715.3B	567.78%	85.43	20.48%
Johnson & Johnson	Buy	$373.6B	10.92%	25.65	16.74%
Merck & Co. Inc.	Buy	$260.9B	13.36%	21.26	19.23%
Novo Nordisk A/s	Buy	$472.8B	280.83%	34.03	35.01%
Abbvie Inc	Buy	$323.5B	109.61%	63.74	9.22%

About Biogen Inc.

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Organization	Biogen Inc.
Employees	7570
CEO	Mr. Christopher A. Viehbacher
Industry	Health Technology

Important FAQs about investing in Biogen Inc. from India :

What is Biogen Inc. share price today?

Biogen Inc. (BIIB) share price today is $164.23.

Can Indians buy Biogen Inc. shares?

Yes, Indians can invest in the Biogen Inc. (BIIB) from India.

With INDmoney, you can buy Biogen Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biogen Inc. at zero transaction cost.

How can I buy Biogen Inc. shares from India?

It is very easy to buy Biogen Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biogen Inc. be purchased?

Yes, you can buy fractional shares of Biogen Inc. with INDmoney app.

What are the documents required to start investing in Biogen Inc. stocks?

To start investing in Biogen Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.